Evidence map›Paper›PMID 40630909›Full record

ArticleFrontiers in neurology2025

Reliable monitoring of respiratory function with home spirometry in people living with amyotrophic lateral sclerosis.

Julián Peller, Marcos A Trevisan, Gaston Bujia, Felipe Aguirre, Diego E Shalom, Alan Taitz, Stephanie Henze, Silviya Bastola, Jason Osik, Ryan A Shewcraft and 13 more

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Julián PellerPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Marcos A Trevisan *Peter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Gaston BujiaPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Felipe AguirrePeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Diego E ShalomUniversidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Física - CONICET - Universidad de Buenos Aires, Instituto de Física Interdisciplinaria y Aplicada (INFINA), Buenos Aires, Argentina.
Alan TaitzPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Stephanie HenzePeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Silviya BastolaPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Jason OsikBristol Myers Squibb, Cambridge, MA, United States.
Ryan A ShewcraftBristol Myers Squibb, Cambridge, MA, United States.
Peng JiangBristol Myers Squibb, Cambridge, MA, United States.
Joel SchwartzBristol Myers Squibb, Cambridge, MA, United States.
Terry Heiman-PattersonDepartment of Neurology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Michael E ShermanDepartment of Medicine, MCG-Hearst Health, Drexel University College of Medicine, Philadelphia, PA, United States.
Matthew F WippermanRegeneron Pharmaceuticals, Tarrytown, NY, United States.
Oren LevyRegeneron Pharmaceuticals, Tarrytown, NY, United States.
Guofa ShouEli Lilly and Company, Boston, MA, United States.
Karl A SillayPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Lyle W OstrowDepartment of Neurology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Ernest FraenkelDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.
James D BerrySean M. Healey and AMG Center for ALS, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Indu Navar BinghamPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.
Esteban G RoitbergPeter Cohen Foundation dba Everything ALS, Seattle, WA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Monitoring respiratory function is essential for assessing the progression of Amyotrophic Lateral Sclerosis (ALS) and planning interventions. Remote pulmonary function testing offers a promising alternative to in-clinic visits by reducing participant burden and enabling more frequent and accessible measurements. Methods: To evaluate the feasibility and reliability of home-based spirometry in ALS, we built on the Radcliff Study, a fully remote, longitudinal, exploratory study conducted at home by 67 people with ALS (pALS). After an initial training period, participants managed their coaching autonomously, performing spirometry independently or requesting assistance from trained personnel. Results: We demonstrate that combining flexible coaching with a predefined automatic quality control protocol yields consistent and reliable spirometry results for tracking respiratory function over time. This approach reveals that home-measured Slow Vital Capacity (SVC) and Forced Vital Capacity (FVC) evolve similarly and follow a linear trajectory throughout the study period (7.7 ± 4.0 months), in both slow and fast progressor subpopulations. Discussion: The observed linearity in respiratory trajectories supports the potential for early and accurate estimation of progression, reinforcing the feasibility of less frequent monitoring without compromising assessment precision and reducing the burden on both pALS and the healthcare system. Furthermore, our results align with reported in-clinic pulmonary tests, validating remote monitoring as a means to promote more equitable and accessible clinical trial designs.

Indexed as

amyotrophic lateral sclerosis (ALS)home spirometryproctoringpulmonary function testtelemedicine

Identifiers

PMID40630909
PMCPMC12235912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.